Attached files
| file | filename |
|---|---|
| EX-23.2 - EX-23.2 - Acer Therapeutics Inc. | d890540dex232.htm |
| S-1/A - S-1/A - Acer Therapeutics Inc. | d890540ds1a.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acer Therapeutics Inc.
Newton, Massachusetts
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Amendment No. 2 to the Registration Statement (No. 333-238192) of our report dated March 18, 2020, relating to the consolidated financial statements of Acer Therapeutics Inc. appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Boston, Massachusetts
June 3, 2020